Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
macular degeneration
Pharma
Eylea HD sales jump in Q3 but Regeneron still cedes market share
While sales of Regeneron's high-dose version of Eylea were up 29% sequentially, this didn't translate to a bump in Eylea franchise sales in the U.S.
Kevin Dunleavy
Oct 31, 2024 11:37am
Regeneron touts Eylea HD launch, warns of potential approval delay
Aug 1, 2024 11:15am
Roche's eye disease meds Vabysmo, Susvimo show extended efficacy
Jul 18, 2024 11:37am
Bayer de-emphasizes the impact of Roche's Vabysmo on Eylea sales
May 14, 2024 11:46am
Dupixent COPD delay possible, Eylea down 2%, Regeneron says
May 2, 2024 12:00pm
Roche's juggernaut Vabysmo routs analyst consensus
Apr 24, 2024 11:29am
